Is<sup>211</sup>At Really Happening?
Beyond the 177Lu-based radiopharmaceuticals targeting somatostatin receptor and prostate-specific membrane antigen, there are new therapeutic radiopharmaceuticals that can potentially reach the market within the next 10 y. These molecules are labeled with 67Cu, 90Y, 131I, 161Tb, 188Re, 211At, 212Pb
Authors
- Richard Zimmermann (ORCID: https://orcid.org/0000-0002-9189-3443)
Institutions
- MedinCell (France) (FR)
- Chrysalis BioTherapeutics (United States) (US)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-03-27
- DOI
- https://doi.org/10.2967/jnumed.125.269699
- Citations
- 7
- Primary Topic
- Amino Acid Enzymes and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 7.78